Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for cancer patients. The company specializes in epigenetic modulation and targeted therapies aimed at overcoming resistance mechanisms and improving outcomes in difficult-to-treat tumors. Headquartered in Waltham, Massachusetts, Syndax leverages a deep pipeline of small-molecule inhibitors designed to address both solid tumors and hematologic malignancies through innovative mechanisms of action.
The company’s lead asset, entinostat, is a selective histone deacetylase (HDAC) inhibitor being evaluated in combination with immune checkpoint inhibitors and chemotherapy in breast, lung, and other solid tumors. Syndax is also developing revumenib (SNDX-5613), a first-in-class menin inhibitor targeting acute leukemias driven by KMT2A rearrangements and NPM1 mutations. Both programs are advancing through mid- and late-stage clinical trials across the United States, Europe, and Australia, with collaborations that include academic and industry partners to optimize trial design and patient access.
Founded in 2007, Syndax has built a leadership team with extensive experience in oncology drug development and regulatory affairs. Michael T. Goldsmith serves as President and Chief Executive Officer, guiding the company’s strategic vision and clinical development activities. The management team includes seasoned executives in research, clinical operations, and business development, all working toward accelerating the delivery of new therapeutic options for patients with limited treatment choices.
Looking ahead, Syndax is committed to expanding its pipeline through both internal discovery programs and external collaborations. The company’s strategic focus on epigenetics and precision medicine aims to deliver treatments that can be tailored to specific cancer subtypes and patient populations. With multiple ongoing trials and a growing body of clinical data, Syndax remains dedicated to its mission of improving survival and quality of life for cancer patients worldwide.
AI Generated. May Contain Errors.
